Copyright
©The Author(s) 2020.
World J Gastroenterol. Jan 28, 2020; 26(4): 375-382
Published online Jan 28, 2020. doi: 10.3748/wjg.v26.i4.375
Published online Jan 28, 2020. doi: 10.3748/wjg.v26.i4.375
Table 1 Selected comparative effectiveness studies of neoadjuvant therapy vs upfront surgery for pancreatic ductal adenocarcinoma
Ref. | Setting | Neoadjuvant type | Neoadjuvant therapy | Upfront surgery | Comments | ||
Sample size | Overall survival | Sample size | Overall survival | ||||
Population-based analyses | |||||||
Mokdad et al[9], 2016 | NCDB | Mixed | 2005 | 26 mo | 6015 | 21 mo | NT: ↓LN, ↓R1/R2 margins |
Retrospective institutional analyses | |||||||
Michelakos et al[46], 2019 | United States | Chemo | 110 | 38 mo | 155 | 21 mo | |
Sugimoto et al[47], 2019 | United States | Mixed | 911 | 23 mo1 | 911 | 19 mo1 | Resected patients: 29 mo vs 21 mo |
Meta-analyses of retrospective studies | |||||||
Versteijne et al[10], 2018 | N/A | Mixed | 17381 | 19 mo1 | 17461 | 15 mo1 | NT: ↓resected rate, ↑R0 rate, ↓LN |
Prospective randomized trials | |||||||
Casadei et al[44], 2015 | Italy | CRT | 181 | 22 mo1 | 201 | 19 mo1 | Did not complete accrual |
Golcher et al[43], 2015 | Germany | CRT | 331 | 17 mo1 | 331 | 14 mo1 | Did not complete accrual |
Jang et al[14], 2018 | South Korea | CRT | 271 | 21 mo1 | 231 | 12 mo1 | Terminated early (improved survival in NT group) |
Van Tienhoven et al[13], 2018 | Netherlands | CRT | 1191 | 17 mo1 | 1271 | 13 mo1 | Presented in abstract only |
Resected patients: 30 mo vs 17 mo | |||||||
Unno et al[15], 2019 | Japan | Chemo | 1821 | 37 mo1 | 180 | 27 mo1 | Presented in abstract only |
- Citation: Cloyd JM, Tsung A, Hays J, Wills CE, Bridges JF. Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research. World J Gastroenterol 2020; 26(4): 375-382
- URL: https://www.wjgnet.com/1007-9327/full/v26/i4/375.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i4.375